We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
The Park Brewery (TPB) is a beer manufacturer. The company raised over £300,000 in its crowdfunding campaign in 2018. It has also managed to increase its sales from 100 pubs to 200. The company's beer is distributed around the UK via eight wholesalers. It also has onboarded notable clients like The Hilton, Honest Burgers, Fullers, and many more. TPB argues that it performed well despite Covid-19. It set up an e-commerce site and sold its products Direct-to-Customers (DTC), having completed around 2,000 home deliveries and gained over 1,700 new customers in 2020 throughout the lockdown. It will use the investment to develop its marketing strategy, increase direct sales, enhance its range, create more employment, and purchase additional tank space to meet demand.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £229,999
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £908,950
Feastr is a UK-based multi-brand cloud kitchen business that delivers restaurant-quality food to a customer's doorstep in 30 minutes or less. The company asserts that operating from cloud kitchens within densely populated areas allows it to exploit the booming food delivery market without the huge overheads associated with bricks and mortar restaurants. Feastr operates its restaurants on aggregators such as Deliveroo, Uber Eats, and Just Eat, capitalising on their huge ready customer base. The company has had sales of over £550,000 since its launch in November 2019. It will use the investment to open three new locations, push its digital marketing campaign with new ideas in 2021, and prepare for its next round of fundraising.

Pitch Rated

49%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £346,487
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
The largest built database comprised of residential and commercial properties in the UK, collated from over 500 reputable sources. Nimbus has information for more than 25m leasehold and freehold properties, in addition to 900k unregistered sites, which can all be easily viewed on a digital map. The company expects their current user base of 5.5k to increase to 240k by 2021 and their monthly sales to grow at a similar rate from £92k in April 2018.
days to go: Expired investment: £366,030
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph